CION Ameerpet
Treatment Explained · Reviewed by CION Oncologists · NABH Accredited
Treating Endometrial Hyperplasia — Usually Hormones, Not Surgery
Most women treated for endometrial hyperplasia never have an operation. The commonest form is managed with a hormone treatment that puts back what the lining has been missing, and in a majority of cases the lining returns to normal. The whole plan turns on one line in your biopsy report — whether atypia was present — because that decides which of two quite different paths you are on. What both paths share is how success is measured: by a repeat biopsy, not by the bleeding settling down. That distinction is the single most useful thing on this page.
- Hormone treatment comes first — for hyperplasia without atypia — surgery is not the starting point
- The hormone IUD is first-line — it delivers treatment directly to the lining and does not rely on memory
- Repeat biopsy proves it worked — settled bleeding is not evidence the lining has returned to normal
- Surgery where atypia is present — and a recognised fertility-sparing alternative if you want to conceive
17+
Cancer Specialists
on Panel
on Panel
35+
Centres
Across India
Across India
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
How the Treatment Plan Is Decided
There are only three inputs, and everything else follows from them. A specialist will want all three before proposing anything.
- Was there atypia? This is the pivot. Hyperplasia without atypia is a hormone problem treated with hormones. Atypical hyperplasia is a precancer, and the standard recommendation is to remove the uterus. See atypical hyperplasia for why the two diverge so sharply.
- Do you want to become pregnant? A current wish to conceive opens the fertility-sparing route even where atypia is present, and it changes which hormone delivery is chosen. It is a clinical input, not a preference to be raised at the end of the appointment.
- What caused it, and can that be changed? Excess body weight, cycles without ovulation, or oestrogen given without a progesterone component all keep producing the same lining. Treating the endometrium without touching the cause is how hyperplasia comes back.
If you are not sure which type your report describes, this page explains how to read it.
Did You Know? The commonest way hyperplasia treatment fails is not that the hormone does not work — it is that nobody checks. Bleeding usually settles within a few months of starting a progestin, and it is easy to read that as cure and stop attending. But the bleeding and the histology are two different things, and the lining can still show hyperplasia after the symptom that led to its discovery has gone. Guidance is therefore explicit that treatment is judged by repeat endometrial sampling, and that sampling continues until consecutive normal results are obtained — not until the woman feels better. Sources: RCOG / BSGE Green-top Guideline No. 67 on the management of endometrial hyperplasia; World Health Organization classification of tumours of female reproductive organs; NCCN Clinical Practice Guidelines in Oncology — Uterine Neoplasms; ESMO–ESGO–ESTRO consensus on endometrial carcinoma.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
What Is Recommended, by Type
| Without atypia | With atypia (EIN) | |
|---|---|---|
| First choice | Progestin therapy. A hormone-releasing intrauterine device is first-line in current guidance; oral progestin where a device is unsuitable or declined. | Total hysterectomy, with the ovary decision taken separately according to menopausal status. |
| If you want to conceive | The same treatment, with a plan for conception once the lining has cleared. Ovulation is often the underlying problem and may need addressing in its own right. | Fertility-sparing high-dose progestin with intensive surveillance — recognised in guidelines, conditional on careful exclusion of an existing cancer first. |
| How response is checked | Repeat endometrial sampling during treatment, continuing until consecutive normal results. Not judged by bleeding. | Repeat sampling at shorter intervals, with an agreed point at which failure to clear means reverting to surgery. |
| When surgery is used instead | No response to hormone treatment, hyperplasia that keeps returning, progression to atypia, or a woman who cannot undertake the surveillance. | It is the default. Hormone treatment substitutes for it only for fertility, or where surgery carries genuine risk. |
| What is never the answer | Endometrial ablation. It destroys the lining instead of removing it for examination and leaves tissue that cannot be sampled afterwards. | Endometrial ablation, and watchful waiting with no sampling. Both remove the ability to know what is happening. |
A note on the word “progestin”. It is a class of hormone, not one drug — the group that opposes oestrogen’s effect on the uterine lining. Which one is used, at what dose and by which route is a decision for the clinician treating you, and it is genuinely individual. If you would like the specifics of what you are taking explained, that is a reasonable thing to ask at your appointment.
Been Offered a Hysterectomy for Hyperplasia?
For the commoner type, that is not the first-line treatment. Bring the report and we will tell you what the guidance actually says for your case.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Treated Properly, Most Hyperplasia Does Not Come Back
The two things that decide it are the right treatment and the follow-up that proves it worked. Both are straightforward when someone is actually running the plan.
The practical detail
What Hormone Treatment Actually Involves, Month by Month
Most descriptions stop at “you will be given a progestin”. Here is what the following year is really like, and where women most often come unstuck.
Fitting the device, or starting the tablets
A hormone-releasing intrauterine device is placed in an outpatient clinic in a few minutes, through the cervix, without a general anaesthetic. It is uncomfortable rather than painful for most women, and cramping for a day or two afterwards is normal. The advantage over tablets is that the progestin sits directly against the lining that needs treating, at a high local dose with far less reaching the rest of the body — and it cannot be forgotten. Oral treatment is used where a device cannot be placed, where the cavity is distorted by fibroids, or where a woman prefers it.
The first three months: irregular bleeding is expected
This is the phase that makes women stop treatment, and it is worth knowing about in advance. Unpredictable spotting and light bleeding are common in the early months, because the lining is being stabilised rather than because anything is wrong. It usually settles, and in many women periods become much lighter than before or stop altogether. If bleeding is heavy, or if it starts again after having settled, that does need reporting — but ordinary irregular spotting early on is part of the treatment working, not a sign of failure.
The first surveillance biopsy
Sampling is repeated during treatment, at an interval set by whether atypia was present. It is the same outpatient procedure as the biopsy that made the diagnosis: a few minutes, a fine flexible tube, cramping like a strong period pain for a short time. The device stays in place; it does not need removing to take a sample. This appointment is the entire point of the plan, and it is the one most often missed, because by then the bleeding has usually settled and the woman feels well. See what an endometrial biopsy involves.
What "regression" means, and when it is believed
Regression means the repeat sample shows a normal lining with no hyperplasia. One normal result is encouraging but not conclusive, which is why guidance recommends continuing until consecutive normal samples are obtained. For hyperplasia without atypia, that usually means sampling at intervals across the first year. Where atypia was present, the sampling is more frequent and the bar is higher, because the consequence of a false reassurance is greater. Only after that does surveillance move to a longer interval or stop.
How long the treatment continues after it has worked
Longer than most women expect, and for a good reason. If the device is removed as soon as the lining is clear, and nothing has changed about the oestrogen exposure that caused the problem, the lining is returned to exactly the conditions that produced hyperplasia in the first place. Guidance therefore supports keeping a hormone-releasing device in place for a prolonged period after regression, particularly in women who remain at risk through weight or anovulation. See can hyperplasia come back.
Treating the cause alongside the lining
This is the half of the treatment that gets least attention and does most of the long-term work. Weight loss reduces the amount of oestrogen the body produces outside the ovaries and has been shown to improve outcomes in this condition; restoring ovulation addresses the missing progesterone at its source; and where oestrogen-only hormone replacement caused the problem, the regimen itself is changed. A treatment plan that addresses only the endometrium is treating the consequence and leaving the mechanism intact. See weight and endometrial risk.
Want a Second View on the Treatment You Have Been Offered?
Bring the biopsy report and whatever plan you were given. We will tell you plainly whether it matches current guidance for your type. The opinion is free.
When to Go Back Before Your Next Appointment
Hyperplasia treatment is generally uneventful, and the surveillance schedule handles the rest. These are the situations that should not wait for the next scheduled visit.
Bleeding that returns after it had settled
Early irregular spotting is expected. Bleeding that stops for months and then comes back is a different signal, and it should be assessed rather than absorbed into the general expectation of irregularity. It does not usually mean something serious, but it is the change that most reliably indicates the lining needs looking at again.
A device that may have moved or been expelled
A hormone-releasing device can be partly or completely expelled, most often in the first months, and sometimes without being noticed. If treatment is being delivered by a device that is no longer correctly placed, the lining is effectively untreated while everyone believes it is being treated. Cramping, unusually heavy bleeding, or threads that feel different are all reasons to have it checked.
You have missed a surveillance biopsy
This is worth ringing about rather than waiting for the system to catch up. A missed appointment is the commonest failure point in hyperplasia care, and it matters most in exactly the women who feel best — symptoms settle long before the histology is confirmed normal. Rebooking is straightforward; the gap is what causes problems.
New pelvic pain, or bleeding after intercourse
Neither is a typical feature of hyperplasia or of its treatment, so both warrant assessment on their own terms rather than being attributed to the known diagnosis. Most causes are benign, but a symptom that does not fit the condition you are being treated for should be looked at rather than explained away by it.
If Hormone Treatment Does Not Work
A minority of linings do not respond, and a further group respond and then relapse. Neither is a disaster, and both are anticipated in the plan — which is precisely why the surveillance biopsies exist.
What happens next depends on which type you started with:
- Without atypia, persisting. The first questions are practical: is the treatment actually reaching the lining, and has the underlying cause changed at all? A device may have been expelled, or oral treatment may not have been taken consistently. Changing route or dose is the usual next step before anything surgical is considered.
- Without atypia, progressing to atypia. If a surveillance sample now shows atypia, the situation has changed category and the recommendation changes with it — to the atypical hyperplasia pathway, where hysterectomy becomes the standard advice.
- With atypia, not clearing within the agreed window. The fertility-sparing route is defined in part by the point at which it stops. If the lining has not regressed by then, guidance is to proceed to surgery rather than continue — and that point should have been agreed before treatment began.
- Recurrence after a clear result. Common enough to plan for, particularly where weight and anovulation are unchanged. It usually means resuming or continuing hormone treatment rather than escalating straight to surgery, but it does prompt a harder look at the cause.
For what surgery involves if it is recommended, see hysterectomy — what to expect and the choice between laparoscopic, robotic and open approaches.
Why Hyperplasia Treatment Is Worth Doing Somewhere That Follows It Through
The treatment is simple. The follow-up that proves it worked is where care is usually lost.
Scan and biopsy in one visit
Follow-up you can actually keep
Slides reviewed, not just the summary line
Fertility taken seriously
45-minute consultations
Decisions for healing, not billing
Take The Next Step
The Treatment Is Straightforward. Being Sure It Worked Is the Part That Matters.
One appointment is enough to set up a plan with a proper end point — and someone whose job it is to see you reach it.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
Endometrial Hyperplasia Treatment — Frequently Asked Questions
What is the first-line treatment for endometrial hyperplasia?
For hyperplasia without atypia, which is the commoner type, current guidance recommends progestin hormone therapy, and specifically favours a hormone-releasing intrauterine device over tablets. The device places the hormone directly against the lining, achieves a high local concentration with much less reaching the rest of the body, and removes the problem of remembering daily medication. Oral progestin remains a reasonable option where a device cannot be fitted, where the uterine cavity is distorted, or where a woman would rather not have one. For atypical hyperplasia the recommendation is different: total hysterectomy is the standard, with hormone treatment reserved for fertility preservation or where surgery would be unsafe.
How long does treatment for endometrial hyperplasia take?
Longer than the symptoms take to settle, which is the source of most confusion. Bleeding usually improves within the first few months, but the treatment is not judged on that. Repeat endometrial biopsies are taken during treatment, and guidance recommends continuing until consecutive normal samples confirm the hyperplasia has resolved — which typically means sampling across the first year. Even after that, a hormone-releasing device is often left in place for a prolonged period, particularly in women whose underlying risk from weight or anovulation has not changed, because removing it returns the lining to the conditions that produced the problem.
Will I need a hysterectomy?
Probably not, if your biopsy showed hyperplasia without atypia. Surgery is not first-line for that type and is generally reserved for women whose hyperplasia does not respond to hormone treatment, keeps returning, progresses to atypia, or who are unable to attend for the surveillance sampling that makes non-surgical management safe. If your biopsy showed atypical hyperplasia, hysterectomy is the standard recommendation — not because it has become cancer, but because it removes the precancer definitively and allows the whole lining to be examined for a carcinoma the biopsy could not reach. Even then, fertility-sparing hormone treatment is a recognised alternative for women who want to conceive.
Is endometrial ablation an option instead of hormone treatment?
No, and this is worth being clear about because ablation is offered for heavy bleeding in other contexts. Ablation destroys the lining rather than removing it, which means the tissue cannot be examined, and it leaves behind pockets of endometrium that are afterwards very difficult to sample. In a woman with hyperplasia, that combination removes the ability to know whether the condition has resolved or progressed — the exact thing the surveillance biopsies exist to establish. It is not an accepted treatment for endometrial hyperplasia of either type. If it has been suggested to you, ask for the reasoning and consider a second opinion.
Does losing weight help treat endometrial hyperplasia?
Yes, and it is part of the treatment rather than general advice attached to it. Fat tissue produces oestrogen independently of the ovaries, so excess body weight maintains exactly the hormonal state that causes the lining to overgrow — and it continues doing so throughout hormone treatment. Weight reduction lowers that ongoing stimulus, and is associated with better outcomes in this condition. The same logic applies to restoring ovulation where cycles have been anovulatory, and to changing an oestrogen-only hormone replacement regimen. Treating the lining without addressing what is driving it is why hyperplasia recurs in some women after an initially good response.
Medical disclaimer: This page describes how endometrial hyperplasia is treated in general terms and is reviewed by a CION oncologist, following current NCCN, RCOG/BSGE and ESMO guidance. It deliberately names hormone classes rather than individual medicines, because dose and choice are individual clinical decisions. It is not advice about your own treatment. If you are on treatment for hyperplasia and bleeding has returned after settling, contact your clinician rather than waiting for your next appointment.